An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models

被引：0
|
作者：
Hu, S. [1 ]
Marineau, J. [1 ]
Bradley, M. [1 ]
Hamman, K. [1 ]
Alnemy, S. [1 ]
Smith, D. [1 ]
Carulli, J. [1 ]
Chuaqui, C. [1 ]
机构：
[1] Syros Pharmaceut Inc, Drug Discovery, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96 (PB-047
引用
收藏
页码：E39 / E40
页数：2
相关论文
共 50 条
  • [21] Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft models
    Shomali, Maysoun
    Guo, Zhuyan
    Cheng, Jane
    Sullivan, Amy
    El-Ahmad, Youssef
    Sun, Fangxian
    Sidhu, Sukhvinder
    Lee, Joon Sang
    Cai, Hui
    Pollard, Jack
    Debussche, Laurent
    Soria, Chris
    Bouaboula, Monsif
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Preclinical evaluation of intermittent dosing regimens on antitumor and PD activity of SY-5609, a potent and selective oral CDK7 inhibitor, in ovarian cancer xenografts
    Johannessen, L.
    Dworakowski, W.
    Sawant, P.
    Ke, N.
    Lefkovith, A.
    D'Ippolito, A.
    Eaton, M.
    Henry, S. H.
    Hodgson, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S365 - S365
  • [23] Dual targeting of CDK4/6 and CDK7 pathways augments tumor response in breast cancer
    Son, Eugene
    Kim, Sungsoo
    Park, Haram
    Kim, Minah
    Yang, Hee Won
    CANCER RESEARCH, 2024, 84 (06)
  • [24] BTK inhibitor BGB-3111 demonstrates anti-tumor activity in solid tumor models
    Hu, Nan
    Zhang, Jiye
    He, Min
    Zhang, Shuo
    Liu, Yong
    Wang, Lai
    CANCER RESEARCH, 2017, 77
  • [25] In vitro anti-cancer activity of UD-017, a novel potent & highly selective CDK7 reversible inhibitor
    Matsushita, Takashi
    Onuma, Kazuhiro
    Sunamoto, Hidetoshi
    Ogawa, Ayumi
    Ogi, Sayaka
    Hasegawa, Toni
    Kono, Shigeyuki
    Iwase, Noriaki
    Aga, Yasuhiro
    Ushiyama, Shigeru
    CANCER RESEARCH, 2017, 77
  • [26] Telomerase inhibitor GRN163L demonstrates anti-tumor efficacy in small cell lung carcinoma models and an ovarian cancer model
    Go, Ning F., Sr.
    Li, Yong J.
    Chin, Allison C.
    Harley, Calvin B.
    Gryaznov, Sergei M.
    Tressler, Robert L.
    CANCER RESEARCH, 2006, 66 (08)
  • [27] Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer
    Lee, Jeong-Won
    Jeong, Soo Young
    Ryu, Ji Yoon
    Lee, Yoo-Young
    Esun, Paik
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer
    Sujee Jeon
    Ji-Yeob Choi
    Kyoung-Mu Lee
    Sue K. Park
    Keun-Young Yoo
    Dong-Young Noh
    Sei-Hyun Ahn
    Daehee Kang
    Breast Cancer Research and Treatment, 2010, 121 : 737 - 742
  • [29] Q901, a selective CDK7 inhibitor, a potential new strategy for primary and CDK4/6 inhibitor resistant ER-positive breast cancer
    Yu, Donghoon
    Jeon, Yeejin
    Park, Dongsik
    Seo, Mooyoung
    Ahn, Wongyun
    Kim, Jaeseung
    Nam, Kiyean
    CANCER RESEARCH, 2021, 81 (13)
  • [30] Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer
    Jeon, Sujee
    Choi, Ji-Yeob
    Lee, Kyoung-Mu
    Park, Sue K.
    Yoo, Keun-Young
    Noh, Dong-Young
    Ahn, Sei-Hyun
    Kang, Daehee
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (03) : 737 - 742
12345